Accelerate Diagnostics, Inc. news
- The Accelerate Arc System cuts hours of wait time and numerous manual steps to deliver Identification (ID) results
- Unlocks rapid microbial ID from positive blood cultures for the large installed base of MALDI system users
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an in-vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis, today announced the launch of the
Designed for labs with MALDI platforms, the Accelerate Arc Module and BC kit is a novel application of inline centrifugation and automated sample prep techniques, which together with the blood culture (BC) kit, provides a suspension of cleaned microbial cells for direct transfer to a MALDI spotting plate.
Accelerate Arc system now available as a registered IVD
Today we announced the completed registration of the Accelerate Arc system as an IVD with the U.S. Fo
Today we announced the release of new performance data across two studies for the Accelerate Arc module and BC kit at the 32nd European Congress for Clinical Microbiology and Infectious Diseases (ECCMID) located in Lisbon, Portugal 23-26 April 2022.
Two posters featuring performance of the Accelerate Arc System will be presented on Monday April 25th, 12:00- 13:00 hr, Pavilion 3 of the Feira Internacional de Lisboa (FIL).
“The data presented at ECCMID represents an import
- In Patients Who Receive Ineffective Empirical Antibiotics for Blood Stream Infections (BSI), Use of AXDX Was Associated With Reduction in 30-Day Mortality
- Interim Data From Multicenter Study Highlight the Real-World Clinical Utility of Fast Phenotypic Antimicrobial Susceptibility Testing for BSI Across Diverse Healthcare Settings and Patient Populations
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced that it will have 3 data presen
CARB-X is awarding Accelerate Diagnostics, a Tucson, Arizona, USA, biotech company, up to US$578,000 to develop new fiber optic technology to diagnose sepsis or the risk of sepsis. Accelerate would be eligible for up to $2.1 million in additional funds from CARB-X if the project meets certain milestones, subject to available funds.
Sepsis is the body’s overwhelming and life-threatening response to an infection that can lead to tissue damage, organ failure and death. Speed